Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: A long term cohort study

Journal of Hepatology

Volumn 36, Issue 2, 2002, Pages 263-270

  Brunetto, Maurizia Rossana ^a   Oliveri, Filippo ^a   Coco, Barbara ^a   Leandro, Gioacchino ^b   Colombatto, Piero ^a   Gorin, Juliana Monti ^a   Bonino, Ferruccio ^a  

^a Azienda Ospedaliero Universitaria Pisana   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Chronic viral hepatitis; HBeAg minus HBV; Hepatitis B virus; Hepatitis exacerbation; Interferon

Indexed keywords

ALPHA INTERFERON; HEPATITIS B CORE ANTIBODY; HEPATITIS B(E) ANTIBODY; IMMUNOGLOBULIN M; VIRUS DNA;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING; VIROLOGY; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0036168816     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00266-5     Document Type: Article

References (37)

1. Chronic type B hepatitis
2. Hepatitis B virus DNA in the sera of HBsAg carriers - A marker of active hepatitis B virus replication in the liver
3. Analysis of liver, nuclear HBcAg, viral replication and hepatitis B virus DNA in liver and serum of HBeAg versus anti-HBe positive carriers of hepatitis B virus
4. Contribution of low levels of HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection
5. Detection and characterization of hepatitis B virus DNA in serum of HBe antigen-negative HBsAg carriers
6. Presence of hepatitis B virus deoxyribonucleic acid in human tissues under unexpected circumstances
7. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe
8. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen
9. Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis
10. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection
11. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
12. Natural history and prognostic factors for chronic hepatitis type B
13. Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment
14. Interferon alpha-2b treatment of HBeAg negative/serum HBV-DNA positive chronic hepatitis type B
15. A randomized controlled trial of lymphoblastoid IFN-alpha in patients with chronic hepatitis B lacking HBeAg
16. Anti-HBe positive chronic hepatitis B with HBV-DNA in the serum: Response to a 6 month course of lymphoblastoid IFN
17. Long term response to therapy of chronic anti-HBe positive hepatitis B is poor independent of type and schedule of interferon
18. The treatment of chronic viral hepatitis
19. The long term course of chronic hepatitis B
20. The long term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B
21. Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc
22. Fluctuations of viremia aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations
23. Wild-type and 'e' antigen minus hepatitis viruses and course of chronic hepatitis
24. Classification of chronic hepatitis: Diagnosis, grading and staging
25. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
26. Non-parametric estimation from incomplete observation
27. Regression models and life table
28. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study
29. Longterm outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa
30. Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis
31. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B
32. Hepatocellular carcinoma in Italian patients with cirrhosis
33. Peginterferon alfa-2a in patients with chronic hepatitis C
34. Lamivudine as initial treatment of chronic hepatitis B in USA
35. Hepatitis B therapy: The plot thickens
36. Efficacy of lamivudine in patients with HBeAg negative/HBV-DNA positive (pre-core mutant) chronic hepatitis B
37. Long term follow-up of patients with anti-HBe/HBV-DNA positive chronic hepatitis B treated for 12 months with lamivudine